BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27076583)

  • 1. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Tiberi S; Sotgiu G; D'Ambrosio L; Centis R; Abdo Arbex M; Alarcon Arrascue E; Alffenaar JW; Caminero JA; Gaga M; Gualano G; Skrahina A; Solovic I; Sulis G; Tadolini M; Alarcon Guizado V; De Lorenzo S; Roby Arias AJ; Scardigli A; Akkerman OW; Aleksa A; Artsukevich J; Auchynka V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Payen MC; Piana A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2016 Jun; 47(6):1758-66. PubMed ID: 27076583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Tiberi S; Payen MC; Sotgiu G; D'Ambrosio L; Alarcon Guizado V; Alffenaar JW; Abdo Arbex M; Caminero JA; Centis R; De Lorenzo S; Gaga M; Gualano G; Roby Arias AJ; Scardigli A; Skrahina A; Solovic I; Sulis G; Tadolini M; Akkerman OW; Alarcon Arrascue E; Aleska A; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2016 Apr; 47(4):1235-43. PubMed ID: 26965290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
    De Lorenzo S; Alffenaar JW; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Bolhuis MS; van Altena R; Viggiani P; Piana A; Spanevello A; Migliori GB
    Eur Respir J; 2013 Jun; 41(6):1386-92. PubMed ID: 22997218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil.
    Arbex MA; Bonini EH; Kawakame Pirolla G; D'Ambrosio L; Centis R; Migliori GB
    Rev Port Pneumol (2006); 2016; 22(6):337-341. PubMed ID: 27481315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
    Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
    Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina.
    Palmero D; González Montaner P; Cufré M; García A; Vescovo M; Poggi S
    Arch Bronconeumol; 2015 Oct; 51(10):e49-52. PubMed ID: 26026689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Sotgiu G; D'Ambrosio L; Centis R; Tiberi S; Esposito S; Dore S; Spanevello A; Migliori GB
    Int J Mol Sci; 2016 Mar; 17(3):373. PubMed ID: 26985890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases.
    Payen MC; Muylle I; Vandenberg O; Mathys V; Delforge M; Van den Wijngaert S; Clumeck N; De Wit S
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):34-39. PubMed ID: 29297423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.
    Payen MC; De Wit S; Martin C; Sergysels R; Muylle I; Van Laethem Y; Clumeck N
    Int J Tuberc Lung Dis; 2012 Apr; 16(4):558-60. PubMed ID: 22325421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.
    Riccardi N; Alagna R; Saderi L; Ferrarese M; Castellotti P; Mazzola E; De Lorenzo S; Viggiani P; Udwadia Z; Besozzi G; Cirillo D; Sotgiu G; Codecasa L;
    BMC Infect Dis; 2019 Jun; 19(1):564. PubMed ID: 31253115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
    Gonzalo X; Drobniewski F
    J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
    Sotgiu G; Centis R; D'Ambrosio L; Alffenaar JW; Anger HA; Caminero JA; Castiglia P; De Lorenzo S; Ferrara G; Koh WJ; Schecter GF; Shim TS; Singla R; Skrahina A; Spanevello A; Udwadia ZF; Villar M; Zampogna E; Zellweger JP; Zumla A; Migliori GB
    Eur Respir J; 2012 Dec; 40(6):1430-42. PubMed ID: 22496332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.
    Dauby N; Muylle I; Mouchet F; Sergysels R; Payen MC
    Pediatr Infect Dis J; 2011 Sep; 30(9):812-3. PubMed ID: 21378593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
    Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
    Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data.
    Muñoz-Torrico M; Caminero Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Ergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
    Rev Port Pneumol (2006); 2017; 23(1):27-30. PubMed ID: 28043788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
    Tiberi S; Sotgiu G; D'Ambrosio L; Centis R; Arbex MA; Alarcon Arrascue E; Alffenaar JW; Caminero JA; Gaga M; Gualano G; Skrahina A; Solovic I; Sulis G; Tadolini M; Alarcon Guizado V; De Lorenzo S; Roby Arias AJ; Scardigli A; Akkerman OW; Aleksa A; Artsukevich J; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Payen MC; Piana A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
    Clin Infect Dis; 2016 May; 62(9):1188-90. PubMed ID: 26908794
    [No Abstract]   [Full Text] [Related]  

  • 18. Extensively drug-resistant tuberculosis in the United States, 1993-2007.
    Shah NS; Pratt R; Armstrong L; Robison V; Castro KG; Cegielski JP
    JAMA; 2008 Nov; 300(18):2153-60. PubMed ID: 19001626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges.
    Chavan VV; Dalal A; Nagaraja S; Thekkur P; Mansoor H; Meneguim A; Paryani R; Singh P; Kalon S; Das M; Ferlazzo G; Isaakidis P
    PLoS One; 2020; 15(6):e0234651. PubMed ID: 32544174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.